CDK4 and breast carcinoma: For example, two neo-adjuvant clinical trials, including palbociclib (CDK4/6i) plus endocrine therapy, showed that increased IFN/STAT1 signaling in ER+ breast cancers were associated with elevated immune checkpoint levels, endocrine resistance, and poor outcome [168].